U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H27N.ClH
Molecular Weight 329.907
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUDIPINE HYDROCHLORIDE

SMILES

Cl.CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=USUUKNCFNKZGEY-UHFFFAOYSA-N
InChI=1S/C21H27N.ClH/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19;/h4-13H,14-17H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H27N
Molecular Weight 293.4458
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Budipine is an antiparkinsonian drug, which was developed by Byk Gulden (now Takeda) for the treatment of Parkinson's disease. The drug has multiple mechanisms of action: it was found to interfere with dopamine biosynthesis, mainly by inhibiting MAO-B enzyme and stimulating aromatic L-amino acid decarboxylase. Also the drug inhibits the dopamine re-uptake and has weak affinity to NMDA and muscarinic receptors. Budipine passes the blood-brain barrier, is metabolized by hydroxylation, and is excreted by both in urine and feces within 24 h.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P27338
Gene ID: 4129.0
Gene Symbol: MAOB
Target Organism: Homo sapiens (Human)
5.0 µM [IC50]
Target ID: Q01959
Gene ID: 6531.0
Gene Symbol: SLC6A3
Target Organism: Homo sapiens (Human)
11.0 µM [IC50]
Target ID: P20711
Gene ID: 1644.0
Gene Symbol: DDC
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PARKINSAN

Approved Use

For combination therapy of Parkinson's disease.

Launch Date

1996
PubMed

PubMed

TitleDatePubMed
[Synthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines].
1984
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
2001 Aug
Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration.
2001 Jun
A new strategy for antidepressant prescription.
2010
Patents

Patents

Sample Use Guides

The dosage is determined individually. The treatment should start with 3 times daily 10 mg budipine hydrochloride. If necessary, the daily dose should be increased at the earliest after 1 week to 3 x 20 mg budipine hydrochloride or 2 x 30 mg budipine hydrochloride.
Route of Administration: Oral
In Vitro Use Guide
10(-7), 10(-8), 10(-9) mol/l of budipine significantly reduced release of TNF-alpha and Il-6 in PBMC and decreased apoptotic cell death after 50 hours and 74 hours in the SH-SY 5Y cells.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:58:45 GMT 2023
Edited
by admin
on Fri Dec 15 15:58:45 GMT 2023
Record UNII
NBF4Q9307Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUDIPINE HYDROCHLORIDE
MI   WHO-DD  
Common Name English
PARKINSAN
Brand Name English
BUDIPINE HYDROCHLORIDE [MI]
Common Name English
1-TERT-BUTYL-4,4-DIPHENYLPIPERIDINIUM CHLORIDE
Systematic Name English
Budipine Hydrochloride [WHO-DD]
Common Name English
Code System Code Type Description
MERCK INDEX
m2747
Created by admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
PRIMARY Merck Index
PUBCHEM
3030419
Created by admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
PRIMARY
FDA UNII
NBF4Q9307Q
Created by admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
PRIMARY
EPA CompTox
DTXSID60979889
Created by admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
PRIMARY
EVMPD
SUB35026
Created by admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
PRIMARY
RXCUI
236892
Created by admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
PRIMARY RxNorm
SMS_ID
100000128225
Created by admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
PRIMARY
CAS
63661-61-0
Created by admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
PRIMARY
ECHA (EC/EINECS)
264-388-5
Created by admin on Fri Dec 15 15:58:45 GMT 2023 , Edited by admin on Fri Dec 15 15:58:45 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY